With 101 million people living with diabetes and another 136 million in the prediabetic stage, India is fast emerging as a key market for GLP-1 agonist therapies
or ii) by one-way ANOVA followed by a KruskalWallis nonparametric test ( a )
Compared to D&E only, Semaglutide 2.4 mg led to marginally fewer cardiovascular events and knee replacements, and less time with obesity-related complications mostly due to prediabetes reversal and as such a delay in T2D occurrence, and a reduction in sleep apnea prevalence (Table 1)
How your body reacts to weight reduction makes losing weight and maintaining it challenging
While it is effective at lowering blood sugar and helping with weight loss, there is ongoing research about how it affects the stomach and intestines, including the risk of peptic ulcers
This tailored approach complements the medication by addressing other aspects like diet and exercise, setting you up for sustainable success